Caltag Medsystems

RevMAb Biosciences

RevMAb Biosciences USA, Inc. is a biotechnology company focused on the development of monoclonal antibodies using a revolutionary technology that does not require cell fusion and hybridoma generation. Their rabbit and goat monoclonal antibodies are developed from a broad range of antigen-specific B cells that are inaccessible to traditional hybridoma technology. After extensive screening and clone selection, RevMAb antibodies are purified and recombinantly produced from an animal-origin-free source.

The RevMAb team consists of pioneers in optimising and transforming rabbit hybridoma technology for commercial application, and developing rabbit monoclonal antibodies for research, diagnostic and therapeutic use. With years of experience and strong expertise in antibody development, RevMAb's team of scientists aim to revolutionise antibody generation and develop high-quality products in order to "reveal true science".

RevMAb Biosciences offers a broad range of antibodies against proteins of the histone family. This includes antibodies against histone modifications such as acetylation, phosphorylation and methylation of different histones. It also includes point mutation-specific antibodies, for example, against Histone H3.3 G34V, G34W and G34R that are of pathological relevance. In comparison to regular monoclonal antibodies, rabbit monoclonal antibodies excel in their specificity and high sensitivity at the same time. RevMAb is currently focused on developing novel point mutation antibodies, aiming to produce high-quality IHC and diagnostic tools for researchers. They are also providing consistent and reliable secondary goat monoclonal antibodies.

The collaboration between RevMAb Biosciences and AdipoGen Life Sciences allows us to bring the RevMAb product range to our UK & Ireland customers.

Technology Overview